Canary Appoints Dr. Michael Lincoff as Chief Clinical Officer to Lead Clinical Development of First-in-Class Dual Gene Silencing Therapy for Obesity
Renowned Cleveland Clinic cardiologist and lead author of the landmark SELECT trial joins Canary to advance CCT-217 into Phase 1 trials. New York, October 14, 2025 – Canary Cure Therapeutics, a biotechnology company pioneering dual gene silencing therapies for obesity and metabolic disease, today announced the appointment of Dr. Michael Lincoff, MD as Chief Clinical Officer.Dr. […]
